Coverage of ASH’s newest clinical meeting, featuring top experts in hematologic malignancies discussing the latest developments in clinical care and answering challenging patient care questions.

Ruben A. Mesa, MD: Treating Myelofibrosis After Ruxolitinib “Failure”

Melissa A. Crawley, MD: How Can We Enroll More Young Patients in Clinical Trials?

Jennifer R. Brown, MD, PhD: Ibrutinib and Atrial Fibrillation Risk in RCTs

Aziz Nazha, MD: How Do TP53 Mutation Characteristics Affect MDS Outcomes?

Jonathan Friedberg, MD: Treating Highly Aggressive Lymphomas

Joseph M. Connors, MD: Optimizing Therapy, Minimizing Toxicity in Hodgkin Lymphoma

Hetty Caraway, MD: Improving Classification in High-Grade MDS

Bhagirathbhai Dholaria, MBBS: Overlapping Myeloma and CLL: Double Trouble?

Jennifer R. Brown, MD, PhD: The Changing Definition of “High-Risk” CLL

Brad Schenkel, MSc: Predicting Hospitalizations, ER Visits Among CLL Patients

Jaleh Fallah, MD: Is the Combo of Abbreviated Chemo Plus Radiation Therapy a Viable Option for DLBCL Patients?

Asher Alban Chanan-Khan, MD: Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL

Ksenia Romanova, MD: Age, Sex, Timing of Treatment Predict Avascular Necroses in Children with ALL

Collaborative Care Delivery Reduces Travel Burden for AML Patients

Highlights of the 2015 ASH Meeting on Hematologic Malignancies

HIV-Associated Lymphoma: Treatment Patterns and Survival in the Antiretroviral Era

The Future of Clinical and Translational Research in Hematologic Malignancies

Daratumumab Safe in Relapsed/Refractory Multiple Myeloma Patients

back to top